US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ ...

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

The US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) today launched new advertisements urging ...

The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

The combination of Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) and Citius Pharmaceuticals’ (Nasdaq: CTXR) Lymphir ...

Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III ...

Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director ...

Geron Corporation has secured $375 million to support the US and potential EU launch of Rytelo and pipeline development. The ...

Aurinia Pharmaceuticals (Nasdaq: AUPH) has announced a major strategic overhaul, reducing its workforce by almost half to focus on driving Lupkynis (voclosporin) growth. The changes, which will also ...

Almirall (BME: ALM), the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...